Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Clin Cancer Res. 2016 Jan 5;22(9):2250–2260. doi: 10.1158/1078-0432.CCR-15-2276

Figure 5. Intermittent, longer-term PI3K inhibition is as effective as metronomic inhibition in combination with anti-estrogen therapy for ER+ breast cancer.

Figure 5

Mice (n=7–9/group) bearing (B) MCF-7 tumors, (C) T47D/FR tumors, or (D) HCI-003 patient-derived xenografts were treated as indicated in (A). In (C), mice were treated with fulv starting at the time of xenografting, and fulv was stopped after 6.5 wk of GDC-0941/fulv treatment. Mean + SEM is shown. *p≤0.05 compared to vehicle-treated group, or as indicated with brackets. #p≤0.05 compared to fulvestrant-treated group. &p≤0.05 compared to GDC-0941-treated group at same dose/schedule. Statistical analysis of (B) included data up to 6.5 wk.